CDER Reviewers Showcase Speed In 2019 With 11 Novel Drugs Approved Within Six Months

Median review time held steady in 2019, but the percentage of NDAs the US FDA approved within six months jumped compared to recent years, a performance upswing all the more impressive because of the relatively high number of applications involved.